Medium materiality6/10
Guggenheim Raises Neurocrine Biosciences Price Target to $224
Why it may matterVerify against the original reporting
Bullish analyst revision with substantial implied upside, though it remains a single-firm forecast.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raised its price target for NBIX to $224, versus the posted price of $164.85, indicating notable potential upside. Analyst targets are opinions, not guarantees.
- Target: $224; posted price: $164.85.
- Analyst: Delma Caiati at Guggenheim.
Key facts
- 01
Target: $224
- 02
Posted price: $164.85
- 03
Analyst firm: Guggenheim
- 04
Analyst: Delma Caiati
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.